10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Incyte Corporation has announced that the Phase III trial of Jakafi (ruxolitinib) in steroid-refractory or steroid dependent chronic graft-versus-host disease (GVHD) met its primary endpoint of superior overall response rate (ORR) at week 24, compared to best available therapy (BAT). 23 July 2020
The transthyretin amyloidosis (ATTR) market is expected to grow from $585 million in 2019 to $14.1 billion in 2029 across the seven major markets, according to GlobalData. 23 July 2020
Dutch biotech firm Synaffix today announced that Swiss oncology-focused drug discovery firm ADC Therapeutics has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix’ site-specific conjugation technologies. 23 July 2020
The UK’s capability to manufacture vaccines has received a substantial boost today, as the government announces an additional £100 million ($127 million) to ensure that any successful COVID-19 vaccine can be produced at scale in the UK. 23 July 2020
Swiss pharma giant Roche has presented detailed results from the Phase III Archway study of its investigational Port Delivery System (PDS). 23 July 2020
Putting the final nail in the coffin for its non-alcoholic steatohepatitis (NASH) drug candidate, French metabolic specialist Genfit today announced the discontinuation of the RESOLVE-IT Phase III clinical trial of elafibranor in adults with NASH and fibrosis. 23 July 2020
Shares of Swiss pharma giant Roche were down more than 2% in early trading today, after it revealed that second-quarter 2020 sales fell 9.6% to 14.1 billion Swiss francs ($15.20 billion). Factoring out the strength of the franc, revenue dropped 4%. 23 July 2020
Adding to a major supply deal with the UK earlier this week, today Pfizer and German partner BioNTech announced an agreement with the US Department of Health and Human Services and the Department of Defense to meet the government’s Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. 22 July 2020
Shares in US biotech Biogen were up by 1.5% following 90 minutes of trading on Wednesday after the company presented its second quarter financial results. 22 July 2020
Japanese drugmaker Daiichi Sankyo has teamed up with Paris-based cancer research institute Gustave Roussy in a multi-year, multi-study research collaboration. 22 July 2020
The USA’s Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness and value of obeticholic acid (OCA), from Intercept Pharmaceuticals (Nasdaq: ICPT), for the treatment of non-alcoholic steatohepatitis (NASH) with fibrosis. 22 July 2020
Oral Janus kinase (JAK) inhibitor Rinvoq (upadacitinib) 15mg and 30mg, once daily monotherapy met both primary and all secondary endpoints in Measure Up 2, the second Phase III study in individuals with moderate to severe atopic dermatitis. 22 July 2020
The Seattle-based subsidiary of Hamburg’s Evotec will develop COVID-19 antibodies for the US Department of Defense (DoD), under an $18.2 million contract. 22 July 2020
Gilead Sciences’ shares dipped 1.7% to $76.76 on Tuesday, after it announced that it will invest $300 million to acquire a 49.9% equity interest in Tizona Therapeutics, a privately held company developing first-in-class cancer immunotherapies, with the intention of buying the whole company later. 22 July 2020
A new project from the European Medicines Agency (EMA) has been established to monitor the efficacy and safety of COVID-19 treatments and vaccines in everyday clinical practice. 21 July 2020
Houston, USA-based CNS Pharmaceuticals has lined up both American and European manufacturers for berubicin, its lead drug candidate for the treatment of glioma brain tumors. 21 July 2020
Privately-held US start-up Jnana Therapeutics has entered a strategic, multi-target collaboration and license agreement with Roche (ROG: SIX) for the discovery of small molecule drugs directed at the solute carrier (SLC) family of metabolite transporters. 21 July 2020
Privately held Danish drugmakers Union Therapeutics and LEO Pharma have completed a transaction for the former to acquire the global rights to the LEO PDE4 inhibitor compound series to be re-named UNI500. 21 July 2020